Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.
about
Post-Genomics and Vaccine Improvement for LeishmaniaCombining cationic liposomal delivery with MPL-TDM for cysteine protease cocktail vaccination against Leishmania donovani: evidence for antigen synergy and protectionTargeting Leishmania major Antigens to Dendritic Cells In Vivo Induces Protective ImmunityCytokine responses to novel antigens in an Indian population living in an area endemic for visceral leishmaniasisDevelopment of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasisCationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements.Identifying vaccine targets for anti-leishmanial vaccine developmentExperimental Validation of Multi-Epitope Peptides Including Promising MHC Class I- and II-Restricted Epitopes of Four Known Leishmania infantum Proteins.The protective immune response produced in dogs after primary vaccination with the LiESP/QA-21 vaccine (CaniLeish®) remains effective against an experimental challenge one year later.Leishmaniasis Vaccine: Where are We Today?Visceral Leishmaniasis: Advancements in Vaccine Development via Classical and Molecular ApproachesHumoral and in vivo cellular immunity against the raw insect-derived recombinant Leishmania infantum antigens KMPII, TRYP, LACK, and papLe22 in dogs from an endemic area.Performance of LBSap vaccine after intradermal challenge with L. infantum and saliva of Lu. longipalpis: immunogenicity and parasitological evaluationVaccines to prevent leishmaniasis.KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasisIn silico analysis of six known Leishmania major antigens and in vitro evaluation of specific epitopes eliciting HLA-A2 restricted CD8 T cell response.Development of Vaccines against Visceral LeishmaniasisEvaluation of Live Recombinant Nonpathogenic Leishmania tarentolae Expressing Cysteine Proteinase and A2 Genes as a Candidate Vaccine against Experimental Canine Visceral Leishmaniasis.Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cellsThe development and clinical evaluation of second-generation leishmaniasis vaccines.Identification of Leishmania infantum chagasi proteins in urine of patients with visceral leishmaniasis: a promising antigen discovery approach of vaccine candidates.Impact of LbSapSal Vaccine in Canine Immunological and Parasitological Features before and after Leishmania chagasi-Challenge.Identification of BALB/c Immune Markers Correlated with a Partial Protection to Leishmania infantum after Vaccination with a Rationally Designed Multi-epitope Cysteine Protease A Peptide-Based Nanovaccine.Resistance to visceral leishmaniasis is severely compromised in mice deficient of bradykinin B2-receptors.Immunology of canine leishmaniasis.DNA Vaccines against Protozoan Parasites: Advances and ChallengesImmunogenicity of the P-8 amastigote antigen in the experimental model of canine visceral leishmaniasis.A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasisImmunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis.FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine.Cutaneous leishmaniasis: progress towards a vaccine.DNA vaccines: a rational design against parasitic diseases.Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems.DNA immunization as an efficient strategy for vaccination.Immunity to visceral leishmaniasis: implications for immunotherapy.Head-to-head comparison of three vaccination strategies based on DNA and raw insect-derived recombinant proteins against Leishmania.Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice.Searching for virulence factors in the non-pathogenic parasite to humans Leishmania tarentolae.A defined subunit vaccine that protects against vector-borne visceral leishmaniasis.Scientific Opinion on canine leishmaniosis
P2860
Q26752532-C749C271-617C-4DDD-A532-B78785F7BBE5Q27304818-FBDB977A-063E-4B23-98A8-60F753509EC1Q27312070-0B18DF5B-B527-45A4-8CBE-D24B48D7AB0AQ28485121-12B7D43F-A8A1-4736-B62A-5E96D15AEA55Q28486287-FC65B768-87A7-4B64-9035-0E17B1513C19Q33367582-0E8637BB-0E7A-4C54-AE19-1F6D073337ADQ33693899-A15967D2-FCB6-4319-8CE2-C404153C6957Q33732102-CD1CF679-EA0A-4906-B54A-E28F7B18E1E3Q33861384-FF329907-CBD6-4558-B83E-B5994F184D3CQ33929859-DBE1B7F2-FAA3-4AA4-AF10-CA658707D7CEQ34076804-897FD62F-CCBC-4D23-B4C2-AB0BB7E30EF6Q34341852-D8BFBA69-3209-40C2-872A-583C76148DC3Q34493859-66654CA6-7B3B-4879-AC4B-F133C2BE27F2Q34511559-48FD787C-6570-416B-ACC2-1E2BA0CEA73CQ35138682-34424F35-045D-43BB-8EC7-70B2051DC92DQ35198753-F4A161EE-FD90-4CAE-97ED-DBA813DC4B49Q35207606-BA2151A2-4130-4FDF-8032-A2BD225E64BDQ35702943-74FF00E1-E35B-4EA6-AB24-FD360D6B139DQ35947234-44392C0A-A3CB-4EB9-A346-CDE2D42DBDDEQ35986733-32BD4240-00E8-4339-AA73-101615B2223DQ36105743-3400FB7B-251B-471A-9389-15FF4FF0D629Q36111326-0A7CC75F-4A48-4322-A3AC-D6F60E2AABEAQ36257481-01E3D673-9D0D-478F-AF80-5A6CEED8AFB3Q36444714-996E59F2-2879-431D-B4EB-EBE443921D09Q36536651-8F057B16-4991-419E-A2DE-7EF7BD402179Q36915067-AA7CBE3A-5239-414C-8AE8-553CC26B7247Q36945381-D903DFE5-34A7-4068-8B64-571238EB2C8EQ37144722-77E01127-B9FF-4916-BFC2-EB7EA0A3DF56Q37225443-4084590E-80F9-4AF4-9956-05AFC6351566Q37229935-D19534F5-D1FA-49F1-BE33-E15569AFD828Q37290119-F64FB9BF-68BF-49EC-980A-3AF7AD1DF7C0Q37682900-2AC56B58-C1B9-4323-803B-F38524F296DAQ37965724-5FF56DBE-F755-41FF-849B-428C64ADA881Q38081358-52C2F76A-2091-41B3-953E-974D72B137E4Q38243220-EE4705AE-6057-4899-91D0-607A390B0664Q41404819-677FAF47-AAD0-4125-9B5C-F3CF626C9DD1Q44390690-A6129098-30FF-4628-8F26-254FBAE413BFQ46024984-5790A173-5A30-4E45-BBBF-2CEC9322685CQ47136266-74E6BB9B-7145-4CE0-9DF5-6C3BE4A36FE4Q47156873-1EB72ADA-4DEB-46CA-9960-8D982C5DDB44
P2860
Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Protective vaccination against ...... type I and II of L. infantum.
@en
Protective vaccination against ...... type I and II of L. infantum.
@nl
type
label
Protective vaccination against ...... type I and II of L. infantum.
@en
Protective vaccination against ...... type I and II of L. infantum.
@nl
prefLabel
Protective vaccination against ...... type I and II of L. infantum.
@en
Protective vaccination against ...... type I and II of L. infantum.
@nl
P2093
P50
P1433
P1476
Protective vaccination against ...... s type I and II of L. infantum
@en
P2093
Davood Eravani
Haideh Darabi
Mohammad Ali Rad
Mohammad Taghikhani
Shahram Jamshidi
Stephanie Sanos
Yasaman Taslimi
P304
P356
10.1016/J.VACCINE.2005.02.009
P407
P577
2005-05-01T00:00:00Z